- Home
- AENT vs CKPT Comparison
AENT vs CKPT Comparison
Compare AENT & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- CKPT
- Stock Information
- Founded
- AENT 1990
- CKPT 2014
- Country
- AENT United States
- CKPT United States
- Employees
- AENT N/A
- CKPT N/A
- Industry
- AENT Durable Goods
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- CKPT Health Care
- Exchange
- AENT Nasdaq
- CKPT Nasdaq
- Market Cap
- AENT 259.4M
- CKPT 214.4M
- IPO Year
- AENT N/A
- CKPT 2017
- Fundamental
- Price
- AENT $6.18
- CKPT $3.71
- Analyst Decision
- AENT
- CKPT Strong Buy
- Analyst Count
- AENT 0
- CKPT 3
- Target Price
- AENT N/A
- CKPT $10.33
- AVG Volume (30 Days)
- AENT 70.0K
- CKPT 1.9M
- Earning Date
- AENT 02-06-2025
- CKPT 11-12-2024
- Dividend Yield
- AENT N/A
- CKPT N/A
- EPS Growth
- AENT N/A
- CKPT N/A
- EPS
- AENT 0.17
- CKPT N/A
- Revenue
- AENT $1,102,718,000.00
- CKPT $47,000.00
- Revenue This Year
- AENT $4.77
- CKPT N/A
- Revenue Next Year
- AENT N/A
- CKPT $151,162.55
- P/E Ratio
- AENT $38.03
- CKPT N/A
- Revenue Growth
- AENT N/A
- CKPT N/A
- 52 Week Low
- AENT $0.70
- CKPT $1.38
- 52 Week High
- AENT $6.69
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- AENT 59.00
- CKPT 58.00
- Support Level
- AENT $5.28
- CKPT $2.98
- Resistance Level
- AENT $6.61
- CKPT $4.15
- Average True Range (ATR)
- AENT 0.66
- CKPT 0.36
- MACD
- AENT -0.03
- CKPT -0.06
- Stochastic Oscillator
- AENT 69.05
- CKPT 75.43
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.